NL-OMON44089撤回3 期
Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial. - The One for Seven Study: effectiveness of oral antipsychotic agents
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:;1. age 18-65 years
- •2. psychotic disorder, including schizophrenia, schizoaffective disorder, delusional disorder or psychosis not otherwise specified
- •3. treatment on an outpatient basis (at the start of the study)
- •4. psychiatrist treating the patient decides that it is appropriate (based on clinical judgement, guidelines, history and symptoms of the patient) to prescribe either penfluridol, olanzapine or risperidone and that there a no decisive contra-indications
- •5. patient is willing to use oral neuroleptic treatment, including penfluridol, olanzapine or risperidone
- •6. able to give informed consent
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:;1.judicial order stating that taking medication is obliged
- •2.patient did use penfluridol during the previous six months
- •3.serious and unstable somatic medical condition
- •4.insufficient proficiency in Dutch language
- •5.women who are pregnant
- •6. patient is on adequate antipsychotic therapy
研究者
相似试验
进行中（未招募）
1 期
Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial.Psychotic disordersEUCTR2014-003834-21-NLErasmus Medical Center Rotterdam180
暂停
不适用
'Effectiveness of Penfluridol (long acting neuroleptic) as compared to second generation oral neuroleptics (olanzapine and risperidone) in psychotic disorder patients: an open label randomized controlled trial'NL-OMON26965Erasmus University Medical Center, RotterdamPsychiatry Department180
进行中（未招募）
1 期
Standard-armed controlled study to assess the impact of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosisMedDRA version: 20.0Level: LLTClassification code 10022612Term: Interstitial lung fibrosisSystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10035754Term: Pneumonitis hypersensitivitySystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10025088Term: Lung fibrosisSystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10022617Term: Interstitial pneumoniaSystem Organ Class: 100000004855EUCTR2014-000861-32-DEJustus Liebig Universität Giessen374
进行中（未招募）
2 期
Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) -A randomized, double-blind, placebo-controlled, parallel group,multi-center, phase II trialJ84.1J68.4Other interstitial pulmonary diseases with fibrosisChronic respiratory conditions due to chemicals, gases, fumes and vapoursDRKS00009822Justus-Liebig Universität Giessen127
已完成
2 期
Effectiveness of pentoxifylline in contrast induced nephropathyRenal failureContrast Nephropathy.N17, N18,IRCT2015102624713N1Vice chancellor for research,Zahedan University of Medical Sciences60